Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says
Executive Summary
Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23
You may also be interested in...
Sparlon Skin Reaction Safety Study Is Unlikely To Erase Need For Black Box
Labeling for Sparlon for attention deficit/hyperactivity disorder will likely carry a black box warning for severe dermatological reactions even if Cephalon conducts an additional safety study to obtain approval
Suicidality Risk With ADHD Drugs Should Be Treated As Class Effect – Cmte.
The risk of suicidality in children receiving drugs to treat attention deficit/hyperactivity disorder should be viewed as a class effect, FDA's Pediatric Advisory Committee recommended March 22
Cephalon’s 2006 Marketing Focus: Sparlon For ADHD, Nuvigil For Narcolepsy
Cephalon will position its attention deficit hyperactivity disorder therapy Sparlon (modafinil) as a "non-traditional" stimulant for inattentive patients with mild-to-moderate hyperactivity